Lonza Group Ltd. is close to a deal to acquire Capsugel Inc. from KKR & Co. LP for over $5 billion, The Wall Street Journal reported, citing people familiar with the matter.

Switzerland-based Lonza is the leading bidder for the New Jersey-based drug-capsule maker in an auction that attracted healthcare and industrial suitors, among others, the report said.

However, the report added that the deal is not guaranteed and that other companies are still circling for a potential transaction. It is also reportedly unclear whether the $5 billion price tag includes debt.

Capsugel last changed ownership when it was acquired by KKR & Co. from Pfizer Inc. for $2.4 billion in 2011.